Karyn Bouhana
- Cancer Research top 10%
- Protease and Inhibitor Mechanisms 3
- Immunology and Allergy top 10%
- Ophthalmology top 5%
-
- Melanoma and MAPK Pathways 3
- RNA and protein synthesis mechanisms 3
-
- HER2/EGFR in Cancer Research 3
-
- Monoclonal and Polyclonal Antibodies Research 5
-
- Lung Cancer Treatments and Mutations 4
- Advanced Breast Cancer Therapies 2
-
- Cancer Mechanisms and Therapy 3
Karyn Bouhana
25 papers receiving 899 citations
Peers
Comparison fields: 5 of 83
- Cancer Research 295
- Immunology and Allergy 87
- Ophthalmology 84
- Molecular Biology 560
- Oncology 192
Countries citing papers authored by Karyn Bouhana
This map shows the geographic impact of Karyn Bouhana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karyn Bouhana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karyn Bouhana more than expected).
Fields of papers citing papers by Karyn Bouhana
This network shows the impact of papers produced by Karyn Bouhana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karyn Bouhana. The network helps show where Karyn Bouhana may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Karyn Bouhana, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2022 | 3 | |
| 3 | 2021 | 6 | |
| 4 | 2021 | 8 | |
| 5 | 2021 | 4 | |
| 6 | 2020 | 5 | |
| 7 | 2016 | 43 | |
| 8 | 2015 | 5 | |
| 9 | 2010 | 53 | |
| 10 | 2010 | 22 | |
| 11 | Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2. | 2009 | 20 |
| 12 | Differential activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 compared to lapatanib in in vivo xenograft models | 2008 | 0 |
| 13 | 2005 | 236 | |
| 14 | 2000 | 6 | |
| 15 | 2000 | 38 | |
| 16 | Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. | 2000 | 129 |
| 17 | 2000 | 14 | |
| 18 | 1999 | 40 | |
| 19 | 1994 | 33 | |
| 20 | Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. | 1990 | 157 |
About Karyn Bouhana
Karyn Bouhana is a scholar working on Genetics, Oncology and Rehabilitation, having authored 26 papers that have together received 946 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (5 papers), Lung Cancer Treatments and Mutations (4 papers), Cancer Mechanisms and Therapy (3 papers), Melanoma and MAPK Pathways (3 papers), Protease and Inhibitor Mechanisms (3 papers), HER2/EGFR in Cancer Research (3 papers), RNA and protein synthesis mechanisms (3 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Cancer Research (295 citations), Immunology and Allergy (87 citations) and Ophthalmology (84 citations). Karyn Bouhana has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include P A Pavco, Zena Werb, Elaine Unemori, Michael J. Banda, Mark L. Rosenblum, James H. McKerrow, Jim Rutka, Jane R. Giblin, Gerard Apodaca and Michael E. Berens. Their work appears in journals such as Journal of Biological Chemistry, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.